Maxigesic vs. standard pain relief after stomach cancer surgery
Treatments studied
Part of Cancer, Digestive system, Pain clinical trials.
This trial compares a new painkiller combination (Maxigesic) with standard pain relief for patients recovering from minimally invasive stomach cancer surgery. The goal is to see if Maxigesic provides better pain control with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 80 years old.
- You have been diagnosed with stomach cancer and are scheduled for a minimally invasive (laparoscopic or robotic) partial or total stomach removal.
- You are in generally good health (ECOG 0–1 and ASA I–III).
- You are not allergic to NSAIDs, opioids, or acetaminophen (Tylenol).
- You are not taking certain medications like opioids, blood thinners, or steroids.
- You weigh at least 45 kg (about 99 pounds).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination pain medicine (Maxigesic) to see how well it controls pain after breast cancer surgery. It may help you need fewer opioids after your operation.
This trial tests if taking Maxigesic® (a combination of two pain relievers) before surgery can lower the amount of a strong IV pain medicine called remifentanil needed during anesthesia. It may help patients have a smoother recovery with fewer side effects.
This trial compares two pain medicines, MAXIGESIC IV and ketorolac, given before and after breast cancer surgery. It aims to see which one better reduces fluid collections (seromas) and bleeding (hematomas) after surgery. If you are having a mastectomy or breast-conserving surgery with lymph node removal and are not getting immediate reconstruction, you may be eligible.
This trial tests a gel (ropivacaine in a special polymer) applied during stomach cancer surgery to reduce pain after the operation. The goal is to help patients recover with less pain and fewer side effects from painkillers.
This study compares different ways to control pain around the time of minimally invasive esophagus surgery. It may help find a method that controls pain better and improves recovery after surgery.
This trial tests a new pain medicine (Tegileridine) against a standard one (Sufentanil) during laparoscopic surgery. It is for patients who have a high risk of nausea and vomiting after surgery.
Hear when a new Stomach Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.